A combination of two probiotics alleviates symptoms and improves quality of life in patients with nonconstipated IBS, a recent clinical trial reports.
Trailing total returns as of 05/12/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) Return VSL.F S&P/ASX 200 [XJO] (^AXJO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback